$523.46
Value $243B
LIN and NAGE stock compared: price, dividend, valuation and results, from SEC filings.
$523.46
Value $243B
$2.01
Value $161M
Linde (LIN) has a market value of $243B and Niagen Bioscience (NAGE) $161M. Over the last year, with dividends, LIN moved +25.3% and NAGE -70.7%. The P/E is 34.6 for LIN and 15.7 for NAGE. Dividend yield: LIN 1.20%, NAGE none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
LIN$243B
NAGE$161M
LIN is 1,507 times NAGE
Revenue, 12 months
LIN$36.2B
NAGE$122M
LIN is 296 times NAGE
Net income, 12 months
LIN$7.0B
NAGE$10M
LIN is 684 times NAGE
Operating margin
LIN25.3%
NAGE3.9%
21.4 points apart
ROIC
LIN11.1%
NAGE5.6%
5.5 points apart
P/E
LIN34.6
NAGE15.7
LIN is 2.2 times NAGE
Dividend yield
LIN1.2%
NAGE0.0%
1.2 points apart
5-year return
LIN+67.7%
NAGE-67.2%
134.9 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
LIN+67.7%
NAGE-67.2%
| Period | LINWith dividends | NAGEWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +25.3%Price +23.6% | -70.7%Price -70.7% |
| 3 years since November 16, 2023 | +33.2%+10.0% a yearPrice +28.2% | +37.7%+11.2% a yearPrice +37.7% |
| 5 years since November 15, 2021 | +67.7%+10.9% a yearPrice +56.7% | -67.2%-20.0% a yearPrice -67.2% |
| 10 years since November 17, 2016 | +431.1%+18.2% a yearPrice +350.1% | -23.0%-2.6% a yearPrice -23.0% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
LINLindeNAGENiagen Bioscience
| Price | $523.46 | $2.01 |
|---|---|---|
| Market value | $243B | $161M |
| Enterprise value (EV) | $264B | $91M |
| P/E | 34.6 | 15.7 |
| P/E, 5-year median | 32.6 | – |
| P/B | 6.2 | 1.9 |
| EV/EBIT | 28.8 | 19.2 |
| Free cash flow yield | 2.1% | – |
| Revenue, 12 months | $36.2B | $122M |
|---|---|---|
| Net income, 12 months | $7.0B | $10M |
| Free cash flow, 12 months | $5.1B | – |
| Earnings per share, 12 months | $15.06 | $0.12 |
| Revenue growth, year on year | 3.0% | 30.0% |
| Revenue growth a year, past | +4.5%over 5 years | +16.9%over 5 years |
| EPS growth a year, past | +25.4%over 5 years | – |
| Gross margin | 47.9% | 63.9% |
|---|---|---|
| Operating margin | 25.3% | 3.9% |
| Net margin | 19.3% | 8.4% |
| ROIC | 11.1% | 5.6% |
| ROE | 18.1% | 13.0% |
| Cash | $3.9B | $70M |
|---|---|---|
| Total debt | $25.2B | $2.1M |
| Net debt / EBITDA | 1.7 | -12.9 |
| Interest cover | 35.5× | – |
| Dividend yield | 1.2% | – |
|---|---|---|
| Dividend per share, 12 months | $6.30 | – |
| Dividend growth a year, past | +9.3%over 5 years | – |
| Buyback yield | 1.9% | 0.2% |
| Shareholder yield | 3.1% | 0.2% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Linde ($243B) is about 1,507.0 times Niagen Bioscience ($161M), at today's prices.
Since November 17, 2016, LIN's price moved +350.1% and NAGE's -23.0%. With dividends: LIN +431.1% (+18.2% a year), NAGE -23.0% (-2.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is 1.20% for Linde and none for Niagen Bioscience. Over the last twelve months they paid $6.30 and – per share.
At today's price, the P/E is 34.6 for LIN and 15.7 for NAGE. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 19.3% for Linde and 8.4% for Niagen Bioscience, and the operating margin 25.3% and 3.9%. Revenue was $36.2B and $122M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.